Sheffield researchers have highighted the risks of using some indigestion tablets alongside a commonly-used osteoporosis treatment.
A study by researchers at Sheffield Teaching Hospitals NHS Foundation Trust and the University of Southern Denmark, published in the Archives of Internal Medicine, showed that patients being treated for osteoporosis with alendronate, who were also taking indigestion medication called a proton pump inhibitor, were less likely to be protected against a hip fracture.
Professor Richard Eastell, of the Sheffield Bone Biomedical Research Unit , said: “It is essential that we examine how different medicines interact with each other, particularly when they are so widely used as the ones in this study.
“This important research is relevant to many people and should help to improve the treatment of patients with both indigestion and osteoporosis.
“These new findings suggest that doctors should consider prescribing treatments other than PPIs to patients who are taking a bisphosphonate for osteoporosis.”